These one-day meetings are programmed by two separate committees covering different topics related to congenital bleeding disorders. The scientific bleeding symposium will touch upon diagnostic aspects of monitoring and managing Extended Half Life products and novel non-replacement therapies, immunological aspect of inhibitor formation in hemophilia, and upcoming novel treatment regimens directed against natural coagulation inhibitors in Hemophilia and Rare Bleeding Disorders. The multidisciplinary symposium will cover general aspects congenital bleeding disorder patients experience during their daily life.  

Two plenary lectures will be given at the start and end of the meeting. The first lecture will be once more be given by Barend Heeren program manager at our Radboudumc Reshape Innovation center. He will discuss the outcome of our 30-days project related to hemophilia patients wellbeing. Prof dr. Thierry Vandendriessche (Brussel, Leuven, Gent) will give an overview about gene therapy with special emphasis to general gene therapy modalities also theoretically applicable in more rare bleeding disorders.